Assembly Biosciences Past Earnings Performance
Past criteria checks 0/6
Assembly Biosciences's earnings have been declining at an average annual rate of -0.4%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 30.1% per year.
Key information
-0.4%
Earnings growth rate
17.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -30.1% |
| Return on equity | -149.0% |
| Net Margin | -854.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Here's Why Assembly Biosciences (NASDAQ:ASMB) Must Use Its Cash Wisely
Aug 17
Will Assembly Biosciences (NASDAQ:ASMB) Spend Its Cash Wisely?
Feb 27We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate
Nov 09Jason Okazaki to succeed John McHutchison as Assembly Biosciences CEO at year-end
Oct 05Assembly Biosciences to discontinue development of inhibitor vebicorvir, cut workforce
Jul 20We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate
Jun 08We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate
Jan 11We're Keeping An Eye On Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate
Sep 03Assembly Biosciences announces resignation of CFO
Jun 02Time To Worry? Analysts Just Downgraded Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Outlook
Mar 24Assembly Biosciences' (NASDAQ:ASMB) Shareholders Are Down 86% On Their Shares
Feb 05We're Hopeful That Assembly Biosciences (NASDAQ:ASMB) Will Use Its Cash Wisely
Dec 14
Assembly Bio inks deal with Door Pharmaceuticals to develop HBV core protein modulators
Nov 16Assembly Biosciences EPS beats by $0.69, beats on revenue
Nov 05Revenue & Expenses BreakdownBeta
How Assembly Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 7 | -61 | 23 | 47 |
| 30 Sep 23 | 0 | -73 | 21 | 0 |
| 30 Jun 23 | 0 | -81 | 22 | 0 |
| 31 Mar 23 | 0 | -89 | 23 | 0 |
| 31 Dec 22 | 0 | -93 | 24 | 66 |
| 30 Sep 22 | 0 | -131 | 24 | 0 |
| 30 Jun 22 | 6 | -127 | 25 | 0 |
| 31 Mar 22 | 6 | -126 | 26 | 0 |
| 31 Dec 21 | 6 | -130 | 29 | 0 |
| 30 Sep 21 | 7 | -109 | 29 | 0 |
| 30 Jun 21 | 36 | -94 | 34 | 0 |
| 31 Mar 21 | 75 | -63 | 37 | 0 |
| 31 Dec 20 | 79 | -62 | 37 | 0 |
| 30 Sep 20 | 83 | -50 | 39 | 0 |
| 30 Jun 20 | 52 | -71 | 36 | 0 |
| 31 Mar 20 | 16 | -97 | 34 | 0 |
| 31 Dec 19 | 16 | -98 | 35 | 0 |
| 30 Sep 19 | 15 | -97 | 34 | 0 |
| 30 Jun 19 | 15 | -93 | 34 | 0 |
| 31 Mar 19 | 15 | -102 | 34 | 0 |
| 31 Dec 18 | 15 | -91 | 30 | 0 |
| 30 Sep 18 | 14 | -68 | 27 | 0 |
| 30 Jun 18 | 13 | -58 | 23 | 0 |
| 31 Mar 18 | 12 | -45 | 19 | 0 |
| 31 Dec 17 | 9 | -43 | 17 | 0 |
| 30 Sep 17 | 6 | -51 | 15 | 0 |
| 30 Jun 17 | 3 | -51 | 14 | 0 |
| 31 Mar 17 | 1 | -47 | 13 | 0 |
| 31 Dec 16 | 0 | -44 | 12 | 0 |
| 30 Sep 16 | 0 | -40 | 12 | 5 |
| 30 Jun 16 | 0 | -36 | 12 | 10 |
| 31 Mar 16 | 0 | -32 | 11 | 15 |
| 31 Dec 15 | 0 | -28 | 11 | 0 |
| 30 Sep 15 | 0 | -27 | 12 | 16 |
| 30 Jun 15 | 0 | -31 | 17 | 15 |
| 31 Mar 15 | 0 | -27 | 15 | 12 |
| 31 Dec 14 | 0 | -24 | 13 | 11 |
| 30 Sep 14 | 0 | -24 | 11 | 13 |
| 30 Jun 14 | 0 | -17 | 5 | 13 |
| 31 Mar 14 | 0 | -20 | 5 | 15 |
| 31 Dec 13 | 0 | -19 | 5 | 15 |
| 30 Sep 13 | 0 | -17 | 5 | 13 |
Quality Earnings: ASMB is currently unprofitable.
Growing Profit Margin: ASMB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ASMB is unprofitable, and losses have increased over the past 5 years at a rate of 0.4% per year.
Accelerating Growth: Unable to compare ASMB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ASMB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: ASMB has a negative Return on Equity (-148.98%), as it is currently unprofitable.